XALKORI® 250 MG CAPSULES
CRIZOTINIB
EXPLORE WHAT'S POSSIBLE.



Xalkori® (Crizotinib) Patient Card

Please complete and show this card to any doctor, nurse, and pharmacist you consult outside of your healthcare professional team.

Your Name: .....

Doctor's Name: .....

Doctor's Telephone Number: .....

Start Date of Crizotinib Treatment: .....

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicine obtained over the counter.

As with all medicines, it is possible that some patients taking Crizotinib may experience side effects.[1,2] If you suffer from any of the following side effects below or other symptoms during treatment with Crizotinib, please consult your doctor (for more details please see corresponding sections in the Patient Brochure):[1,2]

- Liver failure
- Lung inflammation
- Reduction in the number of white blood cells (including Neutrophils)
- Light-headedness, fainting, or chest discomfort (could be signs of abnormal rhythm of the heart)
- Partial or complete loss of vision in one or both eyes
- Severe stomach, intestine, and mouth (gastrointestinal) problems
- Renal cysts in adult patients

For other side effects of Crizotinib in adults with Non-small Cell Lung Cancer (NSCLC), please read the Package Leaflet that is supplied in every package of Crizotinib.

XALKORI 250 MG CAPSULES
CRIZOTINIB
EXPLORE WHAT'S POSSIBLE.

• Xalkori® (Crizotinib) Patient Card

Please complete and show this card to any doctor, nurse, and pharmacist you consult outside of your healthcare professional team.

• Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this patient card. You can also report side effects directly to:

• Executive Directorate of Pharmacovigilance, at Saudi Food and Drug Authority (SFDA):

- SFDA Call Center: 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: http://ade.sfda.gov.sa/
- QR Code:

• Pharmacovigilance Department in the company:

- E-mail: SAU.AEReporting@pfizer.com

This document is approved by the Executive Directorate of Pharmacovigilance at **Saudi Food and Drug Authority (SFDA).**

For extra copies, please send an email with your contact details and the required amount to SAU.AEReporting@pfizer.com

References:
1. Xalkori, Saudi Arabia summary of product characteristics. June 2022.
2. Xalkori, Saudi Arabia Patient Information Leaflet (PIL). June 2022.

Date of Preparation: Jun2025

PP-XLK-SAU-0057